Lapatinib Stada

Lapatinib, the active ingredient in Lapatinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats HER2‑positive metastatic breast cancer and HER2‑positive metastatic gastric cancer.

GNH USA supplies Lapatinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Lapatinib is a targeted therapy that acts on HER2‑driven cancers. - HER2‑positive metastatic breast cancer: improves progression‑free survival when used with trastuzumab and capecitabine. - HER2‑positive metastatic gastric cancer: delays disease progression in combination regimens. - Combination therapy with trastuzumab and capecitabine: enhances antitumor activity in HER2‑positive disease.

Lapatinib may cause a range of adverse reactions.

Common Side Effects: - Diarrhea: frequent loose stools. - Rash: skin irritation, often on the trunk. - Nausea: feeling of sickness, may lead to vomiting. - Fatigue: persistent tiredness. - Hand‑foot syndrome: redness or swelling of palms and soles.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac dysfunction: reduced left ventricular ejection fraction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Interstitial lung disease: breathing difficulties, cough. - QT interval prolongation: risk of cardiac arrhythmias.

Before initiating therapy, clinicians should consider several safety measures. - Cardiac monitoring: assess baseline and periodic ejection fraction. - Hepatic function: check liver enzymes before and during treatment. - Pregnancy avoidance: contraindicated; advise effective contraception. - Drug interactions: review concomitant CYP3A4 modulators. - Dose adjustments: consider in patients with hepatic impairment. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Lapatinib can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase toxicity. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - QT‑prolonging agents (e.g., sotalol): increase risk of arrhythmia.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR. - Digoxin: watch for altered plasma levels. - Hormonal contraceptives: efficacy may be reduced. - Antacids or proton‑pump inhibitors: may affect absorption.